Cargando…

Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?

Minimal/measurable residual disease (MRD) monitoring is progressively changing the management of hematologic malignancies. The possibility of detecting the persistence/reappearance of disease in patients in apparent clinical remission offers a refined risk stratification and a treatment decision mak...

Descripción completa

Detalles Bibliográficos
Autores principales: Assanto, Giovanni Manfredi, Del Giudice, Ilaria, Della Starza, Irene, Soscia, Roberta, Cavalli, Marzia, Cola, Mattia, Bellomarino, Vittorio, Di Trani, Mariangela, Guarini, Anna, Foà, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043164/
https://www.ncbi.nlm.nih.gov/pubmed/36998457
http://dx.doi.org/10.3389/fonc.2023.1152467
_version_ 1784913082253836288
author Assanto, Giovanni Manfredi
Del Giudice, Ilaria
Della Starza, Irene
Soscia, Roberta
Cavalli, Marzia
Cola, Mattia
Bellomarino, Vittorio
Di Trani, Mariangela
Guarini, Anna
Foà, Robin
author_facet Assanto, Giovanni Manfredi
Del Giudice, Ilaria
Della Starza, Irene
Soscia, Roberta
Cavalli, Marzia
Cola, Mattia
Bellomarino, Vittorio
Di Trani, Mariangela
Guarini, Anna
Foà, Robin
author_sort Assanto, Giovanni Manfredi
collection PubMed
description Minimal/measurable residual disease (MRD) monitoring is progressively changing the management of hematologic malignancies. The possibility of detecting the persistence/reappearance of disease in patients in apparent clinical remission offers a refined risk stratification and a treatment decision making tool. Several molecular techniques are employed to monitor MRD, from conventional real-time quantitative polymerase chain reaction (RQ-PCR) to next generation sequencing and digital droplet PCR (ddPCR), in different tissues or compartments through the detection of fusion genes, immunoglobulin and T-cell receptor gene rearrangements or disease-specific mutations. RQ-PCR is still the gold standard for MRD analysis despite some limitations. ddPCR, considered the third-generation PCR, yields a direct, absolute, and accurate detection and quantification of low-abundance nucleic acids. In the setting of MRD monitoring it carries the major advantage of not requiring a reference standard curve built with the diagnostic sample dilution and of allowing to reduce the number of samples below the quantitative range. At present, the broad use of ddPCR to monitor MRD in the clinical practice is limited by the lack of international guidelines. Its application within clinical trials is nonetheless progressively growing both in acute lymphoblastic leukemia as well as in chronic lymphocytic leukemia and non-Hodgkin lymphomas. The aim of this review is to summarize the accumulating data on the use of ddPCR for MRD monitoring in chronic lymphoid malignancies and to highlight how this new technique is likely to enter into the clinical practice.
format Online
Article
Text
id pubmed-10043164
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100431642023-03-29 Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies? Assanto, Giovanni Manfredi Del Giudice, Ilaria Della Starza, Irene Soscia, Roberta Cavalli, Marzia Cola, Mattia Bellomarino, Vittorio Di Trani, Mariangela Guarini, Anna Foà, Robin Front Oncol Oncology Minimal/measurable residual disease (MRD) monitoring is progressively changing the management of hematologic malignancies. The possibility of detecting the persistence/reappearance of disease in patients in apparent clinical remission offers a refined risk stratification and a treatment decision making tool. Several molecular techniques are employed to monitor MRD, from conventional real-time quantitative polymerase chain reaction (RQ-PCR) to next generation sequencing and digital droplet PCR (ddPCR), in different tissues or compartments through the detection of fusion genes, immunoglobulin and T-cell receptor gene rearrangements or disease-specific mutations. RQ-PCR is still the gold standard for MRD analysis despite some limitations. ddPCR, considered the third-generation PCR, yields a direct, absolute, and accurate detection and quantification of low-abundance nucleic acids. In the setting of MRD monitoring it carries the major advantage of not requiring a reference standard curve built with the diagnostic sample dilution and of allowing to reduce the number of samples below the quantitative range. At present, the broad use of ddPCR to monitor MRD in the clinical practice is limited by the lack of international guidelines. Its application within clinical trials is nonetheless progressively growing both in acute lymphoblastic leukemia as well as in chronic lymphocytic leukemia and non-Hodgkin lymphomas. The aim of this review is to summarize the accumulating data on the use of ddPCR for MRD monitoring in chronic lymphoid malignancies and to highlight how this new technique is likely to enter into the clinical practice. Frontiers Media S.A. 2023-03-14 /pmc/articles/PMC10043164/ /pubmed/36998457 http://dx.doi.org/10.3389/fonc.2023.1152467 Text en Copyright © 2023 Assanto, Del Giudice, Della Starza, Soscia, Cavalli, Cola, Bellomarino, Di Trani, Guarini and Foà https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Assanto, Giovanni Manfredi
Del Giudice, Ilaria
Della Starza, Irene
Soscia, Roberta
Cavalli, Marzia
Cola, Mattia
Bellomarino, Vittorio
Di Trani, Mariangela
Guarini, Anna
Foà, Robin
Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
title Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
title_full Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
title_fullStr Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
title_full_unstemmed Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
title_short Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
title_sort research topic: measurable residual disease in hematologic malignancies. can digital droplet pcr improve measurable residual disease monitoring in chronic lymphoid malignancies?
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043164/
https://www.ncbi.nlm.nih.gov/pubmed/36998457
http://dx.doi.org/10.3389/fonc.2023.1152467
work_keys_str_mv AT assantogiovannimanfredi researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies
AT delgiudiceilaria researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies
AT dellastarzairene researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies
AT sosciaroberta researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies
AT cavallimarzia researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies
AT colamattia researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies
AT bellomarinovittorio researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies
AT ditranimariangela researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies
AT guarinianna researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies
AT foarobin researchtopicmeasurableresidualdiseaseinhematologicmalignanciescandigitaldropletpcrimprovemeasurableresidualdiseasemonitoringinchroniclymphoidmalignancies